EP1705480B1 - Testelement zur Analyse von Körperflüssigkeiten - Google Patents

Testelement zur Analyse von Körperflüssigkeiten Download PDF

Info

Publication number
EP1705480B1
EP1705480B1 EP05102290A EP05102290A EP1705480B1 EP 1705480 B1 EP1705480 B1 EP 1705480B1 EP 05102290 A EP05102290 A EP 05102290A EP 05102290 A EP05102290 A EP 05102290A EP 1705480 B1 EP1705480 B1 EP 1705480B1
Authority
EP
European Patent Office
Prior art keywords
body fluid
adhesive substance
test element
application
site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP05102290A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1705480A1 (de
Inventor
Rudolf Dr. Pachl
Hans-Ludwig Griesheimer
Wilfried Dr. Schmid
Martin Frank
Jürgen HOFERER
Branislav Babic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Original Assignee
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL05102290T priority Critical patent/PL1705480T3/pl
Application filed by F Hoffmann La Roche AG, Roche Diagnostics GmbH filed Critical F Hoffmann La Roche AG
Priority to EP05102290A priority patent/EP1705480B1/de
Priority to AT05102290T priority patent/ATE527536T1/de
Priority to ES05102290T priority patent/ES2374541T3/es
Priority to CA2598586A priority patent/CA2598586C/en
Priority to PCT/EP2006/002643 priority patent/WO2006100064A1/de
Priority to CN2006800092030A priority patent/CN101147057B/zh
Priority to JP2008502322A priority patent/JP4825263B2/ja
Publication of EP1705480A1 publication Critical patent/EP1705480A1/de
Priority to US11/859,757 priority patent/US7763470B2/en
Priority to HK08110002.7A priority patent/HK1118606A1/xx
Priority to US12/815,751 priority patent/US8303906B2/en
Application granted granted Critical
Publication of EP1705480B1 publication Critical patent/EP1705480B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5023—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures with a sample being transported to, and subsequently stored in an absorbent for analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/14—Process control and prevention of errors
    • B01L2200/141—Preventing contamination, tampering
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0809—Geometry, shape and general structure rectangular shaped
    • B01L2300/0825—Test strips
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T29/00—Metal working
    • Y10T29/49—Method of mechanical manufacture
    • Y10T29/4998—Combined manufacture including applying or shaping of fluent material
    • Y10T29/49982—Coating
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
    • Y10T436/144444—Glucose

Definitions

  • the present invention relates to the use of an adhesive substance in an analytical test element for determining the concentration of a body fluid. Furthermore, the invention relates to analytical test elements having an adhesive substance.
  • the test strip can remain in one position during the entire concentration determination and does not have to be moved to a measuring position after the sample has been applied.
  • the sample material is capillary forces, the z. B. from a transport element such as a capillary, absorbent fabric or a nonwoven, which generates a capillary action, transported from the place of application to the detection area.
  • test strips are stored sealed before use in the magazine to protect them from dirt and moisture, but after use, the individual storage chambers for the test strips are usually no longer closed, so superfluous applied Blood that sticks to the used test strips may crumble over time and through openings in the magazine may contaminate the instrument, in particular the evaluation optics or other device components.
  • EP 1 413 880 describes a test element according to the preamble of claim 14, but wherein the adhesive substance has another function, namely the sticking of the test element to the skin.
  • the object of the present invention is to overcome the disadvantages of the prior art and the problems mentioned in the introduction. It is intended to provide a high-volume cost-effectively producible diagnostic test element in which the application location is spaced from the detection area. Once applied to the test element body fluid should adhere to the test element to avoid contamination of the environment. On the other hand, the spacing from the point of application to the detection area requires sample transport. To ensure this sample transport, a good wettability of the test element and transmission of body fluid is necessary. The object of the invention is therefore to develop a test element that meets these conflicting requirements. In particular, it is the object of the present invention to avoid the contamination of a measuring instrument containing a magazine in which test elements are remagazine after use.
  • the object is achieved by the use of an adhesive substance or by a system according to the independent claims, preferred embodiments are given in accordance with the dependent claims.
  • the invention describes analytical test elements that facilitate hygienic storage and disposal of used test elements.
  • the invention relates to test elements which are stored after use in a reservoir, wherein on the test elements an adhesive substance is applied, which avoids a crumbling superfluous applied body fluid.
  • the test elements are preferably fluid-conductively coated in the areas in which the body fluid can be applied, transported and detected, and in the areas which can be wetted with body fluid which is not used for the measurement, an adhesive substance can be applied. In this way it is ensured that body fluid can flow from the place of application to the detection area and an analyte concentration can be determined there. At the same time, excess applied body fluid may at least partially interact with the adhesive substance and adhere to the test element.
  • An analytical test element for determining an analyte in a body fluid for use in accordance with the invention includes a detection region in which the analyte is detected and a point of application where the body fluid can be applied to the test element, the detection region being spaced from the application site, wherein at least one Part of a discontinued on the place of application body fluid from the place of application reaches the detection area.
  • the test element further includes a contamination area that borders at least a portion of the application site, wherein at least a portion of the contamination area, an adhesive substance is applied.
  • the adhesive substance adheres to the contamination area of the test element and is furthermore able to interact with a body fluid superfluous on the test element in such a way that the body fluid adheres to the test element at least in part, so that superfluous applied body fluid remains on the test element.
  • a stop of the constituents of the body fluid takes place, which are not volatile.
  • the transportation route is designed to be easily wetted by the body fluid.
  • a capillary acting transport element is used for this purpose, which is hydrophilic coated, for example.
  • a diagnostic test element preferably has a plurality of capillary-acting regions, for example at the application site, to ensure that body fluid can be applied to the test element, to the transport element to transport body fluid from the application site to the detection area, and in the detection area where after wetting with the body fluid an analyte in the body fluid can be detected.
  • hydrophilization methods are possible as they are, for. B. in the prior art WO 99/29435 are called.
  • the wettability is usually sufficient if the liquid in the transport element has a concave meniscus, which is the case when the wetting angle is less than 90 °.
  • test element Under a test element is any form of carrier-bound rapid tests for diagnosis to understand, especially rapid tests in strip form, so-called test strips, in particular for the determination of blood glucose content in diabetics such as in WO 2004/064636 and in EP 1 039 298 described.
  • the test elements are usually constructed of a plurality of superimposed films, which are preferably joined together by lamination or gluing. These films are usually made of plastic, for example polyester.
  • the base film forms, for example, a so-called carrier film on which a spacer film glued, which produces the capillary.
  • the capillary channel can be covered by a so-called cover film.
  • analyte is meant a constituent of the bodily fluid which reacts with detection chemistry in the detection area so that, starting from a certain amount of the analyte, the reaction can be measured in a measuring arrangement.
  • blood is used as a sample liquid to detect blood glucose as an analyte in the detection area and to determine therefrom the concentration of blood sugar.
  • the analyte can react with a detection chemistry and generate a measurement signal.
  • the measurement signals can be detected, for example, by a detection unit in order to determine therefrom the concentration of the analyte in the body fluid. In the case of photo-optical test strips, this can be, for example, a color change; in electrochemical systems, for example, a current signal is generated.
  • the place of application designates the point at which the body fluid is applied by the user to the test element. From there, the body fluid is forwarded, for example via capillary forces in the detection area.
  • the place of application is spaced from the detection area.
  • the analytical test element may include a transport element that transports body fluid from the point of application to the detection area.
  • the adhesive substance is applied in an area that can be contaminated with body fluid, the so-called contamination area.
  • the contamination area describes a region in which superfluously applied body fluid, for example blood, can pass, in particular during application to the test element.
  • the area of contamination is at least partially adjacent to the place of application.
  • the contamination area may include multiple non-contiguous portions, for example, multiple sides adjacent the point of application, such as on the underside of a carrier sheet and on top of a cover sheet. If a transport element is present, then the adhesive substance can also be located next to or along the transport element.
  • adhesive substance is meant a substance which causes superfluous applied body fluid, in particular blood and interstitial fluid or the like. remains after drying of the body fluid on the analytical test element and in particular not, for. As in mechanical stress when handling the analytical test element, after use, for. B. during storage, especially in the Remgazin ist used test element in a magazine, or the disposal crumbles.
  • the aqueous portions of the body fluid dissolve the adhesive substance, so that the adhesive substance and body fluid mix. This mixture dries by evaporation of the liquid, for example in a period of about 10 to 20 minutes, and the dried substance adheres to the attached body fluid to the analytical test element.
  • the drying time is naturally dependent on the ambient climate, in particular the ambient temperature and the humidity, and can vary greatly according to these parameters.
  • adhesive substances are conceivable which ensure adhesion of the sample to the test element immediately after contact with the sample liquid.
  • the adhesive substance is not applied to the application site and / or to the transport element, as this may lead to less sample liquid being available for the measurement, since a part of the sample can interact with the adhesive substance and does not reach the detection area.
  • adhesive substance enters the detection area with the sample and adversely affects the measurement. If adhesive substance is present in the detection area, the application of the detection chemistry or the fixation and / or durability of the dry chemistry or the measurement itself may be impaired.
  • the transport element and / or the detection area is the adhesive substance is preferably selected so that it does not adversely affect the measurement process.
  • the analysis system is then tuned accordingly, e.g. B. so that an increased demand for required sample volume can be accepted.
  • the adhesive substance described is a substance which, without absorbing self-volume, can prevent detachment of dried superfluously applied body fluid, in particular blood, by producing an adhesive connection between body fluid and test element.
  • the aqueous portions of the blood dissolve the adhesive substance, which leads to a solid contact of the body fluid with the carrier material after the body fluid has dried.
  • the adhesive does not create a capillary action that would compete with the capillary at the point of application for the sample fluid.
  • the adhesive substance acts time-delayed with respect to the capillary at the point of application, so that first the detection area is filled with sample and only superfluously applied liquid is bound by the adhesive substance.
  • the force that affects the adhesive substance on the sample at least immediately after the trial order significantly lower than the capillary force with which the sample is transported into the detection area, so that is ensured in this way that the detection area is first filled and only the superfluous applied body fluid with the adhesive substance adheres to the test element.
  • the adhesive substance is preferably applied during the production of the test strip and in this case is mechanically so stably connected to the test element that the adhesion layer is not removed in the subsequent process steps and during handling and transport by mechanical stresses such as bending, torsion or abrasion.
  • the dried excess body fluid that has bound to the adhesive should, after it has dried, adhere so stably to the test element that it remains on the test element during handling by the user, disposal of the test strip, and especially during remagazine.
  • the binding of the adhesive substance to the test element and the binding of the dried excess body fluid in interaction with the adhesive substance on the test element can be physical in nature. In this case, the adhesive substance swells in contact with the liquid and forms a sticky mass during the evaporation of the body fluid, which adheres to the test element.
  • the adhesive substance is polyvinyl acetate (PVAc).
  • PVAc polyvinyl acetate
  • an aqueous dispersion of 35 weight percent PVAc having a thickness of about 60 microns is applied to the analytical test element. Subsequently, the dispersion is dried at about 70 ° for about 30 s and then gives an approximately 17 ⁇ m thick dry layer on the test element.
  • PVAc is available, for example, from Wacker under the trade name Vinnapas®; typical molar masses are 1,000-100,000 g / mol.
  • the adhesive may, for example, with a squeegee, by spraying, dipping, printing, z. As screen printing or pad printing, or casting are applied.
  • the carrier or cover sheet may have a recess in the region of the application site, whereby the hydrophilic coating is accessible and lying open, so that the body fluid can be easily applied to the hydrophilic layer.
  • the recess can z. B. by punching one of the two films before bonding the two films are produced together. This has the advantage, for example, that the adhesive substance can be applied over a large area on the upper side of the cover film and on the underside of the carrier film without having to shield the application site. The subsequent punching, for example, the cover sheet, exposes the hydrophilic layer of the application site.
  • the adhesive substance is applied to the carrier top, either on the entire surface completely or on parts of the carrier film.
  • the detection area can be applied, for example, to the adhesive substance, or it can be applied to areas of the carrier film on which there is no adhesive substance.
  • the application of the reagent to the adhesive substance on the carrier film, or at least part of the detection area is not covered with adhesive substance.
  • Another possible method for producing an analytical test element according to the invention may include the following steps: applying the detection area to a carrier film, preferably on the carrier top and usually only on a small area of the carrier film, applying the adhesive substance to the carrier film, wherein at least a part of the detection area is not covered with adhesive substance, and then drying of the adhesive substance on the carrier sheet of the analytical test element.
  • a structured coating can, for example, be realized by a screen-printing method with a mask which shields at least part of the detection area, or by pad printing with a pressure stamp which has a corresponding recess.
  • one or more analytical test elements to the user in a storage container (magazine), adhesive substance being applied to the test elements so that superfluously applied body fluid remains at the contamination area.
  • one or more test elements according to the invention, to which an adhesive substance has been applied are stored in a storage container, and the analytical test elements are stored after use in the same or in another magazine (remagazine).
  • test strips are sealed before use and packaged tightly to protect them from environmental impact.
  • the seal is broken and the test strips are in open chambers after use when remagazineized.
  • the used test strips would also have to be tightly packed after Remagazinleiter in the same or in another magazine, which means a high technical effort.
  • the application of an adhesive substance according to the invention to the analytical test elements offers a technically simple solution for this, since the adhesive substance adheres to the contamination area of the test element and is furthermore able to interact with a body fluid superfluous on the test element in such a way that the body fluid on the test element at least partially adheres, so that superfluous applied body fluid remains at the contamination area.
  • the analytical test elements according to the invention are particularly suitable for use in systems in which the test strips are remagazine after use.
  • adhesive substances are also used which ensure adhesion of the sample immediately after sample application. In this way, contamination of the device during transportation of a used test strip for Remagazinleiter can be prevented.
  • a system for determining an analyte from a body fluid includes one or more analytical test elements and a reservoir (magazine) for these test elements, the test elements being stored in the reservoir after use.
  • the system preferably includes a measuring instrument with an evaluation unit, in which the detection area can be evaluated and from this the concentration of the analyte can be determined.
  • FIG. 1 shows an example of an analytical test element 1, which includes a cover sheet 2 and a carrier sheet (not visible).
  • the cover sheet 2 has a recess 3 at the point of application to which the body fluid is applied, which causes the hydrophilic intermediate layer 4 to be accessible in the recess 3.
  • a strip 7 of, for example, 7 mm width which has been coated with an adhesive substance in a previous operation, on a tape with several contiguous test elements on top of the cover sheet 2 and optionally a second strip on the underside of the carrier film in the contamination area laminated to the tip of the test elements.
  • the test element band is separated into individual test elements.
  • the edge trimming is punched out before or after singulation along a contour 5, leaving a single test strip with, for example, a 2.8 mm wide blood adhesion strip in the area of the blood application score 3.
  • the remaining section 6 is discarded.
  • FIG. 2 shows an inventive analytical test element 1 with a recess 3, shown in an exploded view.
  • a carrier film 10 in which the recess 3 has been introduced in the form of a V-shaped notch, which may serve, inter alia, the marking of the application, there is a spacer film 11, which the contour and the height (corresponding to the thickness of the spacer film 11) a capillary-active channel 12 determined.
  • the spacer film 11 consists of a double-sided adhesive tape, for example, activated carbon was added to the adhesive composition.
  • On this spacer sheet 11 are a cover sheet 2, a detection area 14, and a protective film 16 to lie.
  • Recess 3 and detection area 14 are mounted so close to one another that the capillary-active zone 12 extends continuously from the free, lying over the recess 3 edge of the recess 3 to the opposite, free edge of the detection area 14.
  • the recess in the spacer film 11, which determines the shape of the capillary-active channel 12 is held slightly longer than cover film 2 and detection area 14 together so that a generally only a few millimeters wide, uncovered gap remains, from which when filling the capillary-active zone 12th Air can escape with sample liquid. This gap remains uncovered by the protective film 16 so that its function remains ensured.
  • the protective film 16 is intended to prevent exposed regions of the adhesive tape of the spacer film 11 from leading to undesired bonding of the test element to objects from the environment.
  • an adhesive substance is applied at least in a part of this range.
  • an adhesive substance on the entire top of the cover sheet 2 and on the entire underside of the carrier film 10 applied an adhesive substance, wherein the recess 3 ensures that the capillary channel 12 is accessible and free of adhesive substance.
  • FIGS. 3 to 6 describes an example of a storage container 20 in which analytical test elements 1 are stored (remagazine) after use.
  • the storage container is inserted into a measuring instrument (not shown).
  • the test element 1, which contains a detection area 14 is pushed out of the reservoir 20 into an order position by the instrument and, if necessary, moved to a second measurement position after application of the body fluid in order to be analyzed there.
  • the spent test element is withdrawn back into the reservoir.
  • an adhesive substance is applied to the test strips 1 in the contamination area so that superfluous applied body fluid remains on the analytical test element and does not contaminate the interior of the device. Without the use of an adhesive substance z. B. dissolve dried blood from the test element and pass through the engagement opening 23 or the Ausschubö réelle 25 in the device interior.
  • the storage container 20 is formed by a drum magazine 21 designed as a cylindrical plastic injection molded part.
  • the guide chambers 22 are arranged distributed in the circumferential direction and extend axially continuously between an end-side engagement opening 23 for a drive unit 24 and an opposite Ausschubö réelle 25.
  • the drum magazine 21 has a central bore 26 with edge teeth 27 for a not shown stepper for flush positioning of researcherschiebenden test element in The feed axis of the drive unit 24.
  • Radially offset outward axial blind holes 28 for receiving a desiccant 29 are arranged.
  • the guide chambers 22 are closed at the end by a (not shown) sealing film.
  • the test strips 1 are held for better guidance in a carriage 30 which is longitudinally displaceable in the respective guide chamber 22 like a drawer.
  • the carriage 30 engages around an end portion of the test strip 1 and is connected thereto via a latching nose 31.
  • a single holding claw 33 of the carriage 30 is provided as a driver.
  • a test strip 1 corresponding to the carriage 30 described above for a reciprocating movement via a single retaining claw 33 as a driver with a single drive ram is positively connected.
  • a spring clip 40 is provided as a drive plunger.
  • the system is not limited to any specific embodiment of a magazine and / or a test element transport.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Clinical Laboratory Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
EP05102290A 2005-03-22 2005-03-22 Testelement zur Analyse von Körperflüssigkeiten Active EP1705480B1 (de)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP05102290A EP1705480B1 (de) 2005-03-22 2005-03-22 Testelement zur Analyse von Körperflüssigkeiten
AT05102290T ATE527536T1 (de) 2005-03-22 2005-03-22 Testelement zur analyse von körperflüssigkeiten
ES05102290T ES2374541T3 (es) 2005-03-22 2005-03-22 Elemento de ensayo para el análisis de fluidos corporales.
PL05102290T PL1705480T3 (pl) 2005-03-22 2005-03-22 Element testowy do analizy płynów ustrojowych
PCT/EP2006/002643 WO2006100064A1 (de) 2005-03-22 2006-03-22 Testelement zur analyse von körperflüssigkeiten
CN2006800092030A CN101147057B (zh) 2005-03-22 2006-03-22 用于分析体液的测试元件
CA2598586A CA2598586C (en) 2005-03-22 2006-03-22 Test element for analysing bodily fluids
JP2008502322A JP4825263B2 (ja) 2005-03-22 2006-03-22 体液の分析用の試験エレメント
US11/859,757 US7763470B2 (en) 2005-03-22 2007-09-22 Test element and method of use for analyzing body fluids
HK08110002.7A HK1118606A1 (en) 2005-03-22 2008-09-09 Test element for analysing bodily fluids
US12/815,751 US8303906B2 (en) 2005-03-22 2010-06-15 Test element for analyzing body fluids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05102290A EP1705480B1 (de) 2005-03-22 2005-03-22 Testelement zur Analyse von Körperflüssigkeiten

Publications (2)

Publication Number Publication Date
EP1705480A1 EP1705480A1 (de) 2006-09-27
EP1705480B1 true EP1705480B1 (de) 2011-10-05

Family

ID=35432656

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05102290A Active EP1705480B1 (de) 2005-03-22 2005-03-22 Testelement zur Analyse von Körperflüssigkeiten

Country Status (10)

Country Link
US (2) US7763470B2 (ja)
EP (1) EP1705480B1 (ja)
JP (1) JP4825263B2 (ja)
CN (1) CN101147057B (ja)
AT (1) ATE527536T1 (ja)
CA (1) CA2598586C (ja)
ES (1) ES2374541T3 (ja)
HK (1) HK1118606A1 (ja)
PL (1) PL1705480T3 (ja)
WO (1) WO2006100064A1 (ja)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391005B1 (en) 1998-03-30 2002-05-21 Agilent Technologies, Inc. Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US7749174B2 (en) 2001-06-12 2010-07-06 Pelikan Technologies, Inc. Method and apparatus for lancet launching device intergrated onto a blood-sampling cartridge
US7025774B2 (en) 2001-06-12 2006-04-11 Pelikan Technologies, Inc. Tissue penetration device
DE60234598D1 (de) 2001-06-12 2010-01-14 Pelikan Technologies Inc Selbstoptimierende lanzettenvorrichtung mit adaptationsmittel für zeitliche schwankungen von hauteigenschaften
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8337419B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7033371B2 (en) 2001-06-12 2006-04-25 Pelikan Technologies, Inc. Electric lancet actuator
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7892185B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7331931B2 (en) 2002-04-19 2008-02-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7232451B2 (en) 2002-04-19 2007-06-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US8360992B2 (en) 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US7297122B2 (en) 2002-04-19 2007-11-20 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7491178B2 (en) 2002-04-19 2009-02-17 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7175642B2 (en) 2002-04-19 2007-02-13 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7229458B2 (en) 2002-04-19 2007-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7708701B2 (en) 2002-04-19 2010-05-04 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
EP2238892A3 (en) 2003-05-30 2011-02-09 Pelikan Technologies Inc. Apparatus for body fluid sampling
ES2490740T3 (es) 2003-06-06 2014-09-04 Sanofi-Aventis Deutschland Gmbh Aparato para toma de muestras de fluido sanguíneo y detección de analitos
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
US8282576B2 (en) 2003-09-29 2012-10-09 Sanofi-Aventis Deutschland Gmbh Method and apparatus for an improved sample capture device
EP1680014A4 (en) 2003-10-14 2009-01-21 Pelikan Technologies Inc METHOD AND APPARATUS PROVIDING A VARIABLE USER INTERFACE
US8668656B2 (en) 2003-12-31 2014-03-11 Sanofi-Aventis Deutschland Gmbh Method and apparatus for improving fluidic flow and sample capture
US7822454B1 (en) 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
EP1751546A2 (en) 2004-05-20 2007-02-14 Albatros Technologies GmbH & Co. KG Printable hydrogel for biosensors
EP1765194A4 (en) 2004-06-03 2010-09-29 Pelikan Technologies Inc METHOD AND APPARATUS FOR MANUFACTURING A DEVICE FOR SAMPLING LIQUIDS
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
EP2265324B1 (en) 2008-04-11 2015-01-28 Sanofi-Aventis Deutschland GmbH Integrated analyte measurement system
EP2166352A1 (de) * 2008-09-17 2010-03-24 F.Hoffmann-La Roche Ag Vorrichtung und Verfahren zum Bestimmen eines Analyten in einer Flüssigkeitsprobe
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US8061004B2 (en) * 2009-08-20 2011-11-22 Roche Diagnostics Operations, Inc. Method of manufacturing a test strip
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US20130116597A1 (en) 2011-11-04 2013-05-09 Phenomenex, Inc. Method and apparatus for acquiring blood for testing
US9573128B1 (en) * 2012-09-06 2017-02-21 SciKon Innovation, Inc. Fluidics device allowing fluid flow between a plurality of wells
CN105683742B (zh) * 2013-06-10 2018-12-25 豪夫迈·罗氏有限公司 制造测试元件的方法和设备
US10035145B2 (en) 2014-12-02 2018-07-31 SciKon Innovation, Inc. Piston assembly and related systems for use with a fluidics device
JP2018512171A (ja) 2015-03-23 2018-05-17 シコン イノベーション，インク． 流体装置と共に使用するための方法および関連システム
KR101558323B1 (ko) * 2015-03-27 2015-10-12 보스웰코리아(주) 자동차 휠용 발광장치
WO2016168692A1 (en) 2015-04-17 2016-10-20 Emmet Welch Method and apparatus for handling blood for testing
GB201721385D0 (en) * 2017-12-20 2018-01-31 Diagnostics For The Real World Ltd Device for sample analysis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4774192A (en) * 1987-01-28 1988-09-27 Technimed Corporation A dry reagent delivery system with membrane having porosity gradient
US5104640A (en) * 1989-03-17 1992-04-14 Wescor, Inc. Fixative composition for fixing blood smears to slides
US5344754A (en) * 1993-01-13 1994-09-06 Avocet Medical, Inc. Assay timed by electrical resistance change and test strip
JPH10319018A (ja) * 1997-05-16 1998-12-04 Eiken Chem Co Ltd 流路切断部位を有するクロマトグラフ装置
DE19753848A1 (de) 1997-12-04 1999-06-10 Roche Diagnostics Gmbh Modifikation von Oberflächen zur Steigerung der Oberflächenspannung
DE19753847A1 (de) * 1997-12-04 1999-06-10 Roche Diagnostics Gmbh Analytisches Testelement mit Kapillarkanal
DE19912365A1 (de) * 1999-03-19 2000-09-21 Roche Diagnostics Gmbh Mehrschichtiges analytisches Hilfsmittel
DE10003507B4 (de) * 2000-01-27 2004-06-03 Knoll, Meinhard, Prof. Dr. Vorrichtung und Verfahren zur Entnahme von Flüssigkeiten aus körpereigenem Gewebe und Bestimmung von Stoffkonzentrationen in dieser Flüssigkeit
EP1413880B1 (en) * 2001-07-27 2015-09-02 ARKRAY, Inc. Analyzing instrument
AU2002351532A1 (en) * 2001-11-29 2003-06-10 Agresearch Limited Method of sampling
DE10302501A1 (de) 2003-01-23 2004-08-05 Roche Diagnostics Gmbh Vorrichtung und Verfahren zur Aufnahme einer Körperflüssigkeit für Analysezwecke
EP2508867A1 (en) * 2005-06-24 2012-10-10 Board Of Regents, The University Of Texas System Systems and methods including self-contained cartridges with detection systems and fluid delivery systems

Also Published As

Publication number Publication date
US8303906B2 (en) 2012-11-06
PL1705480T3 (pl) 2012-03-30
ATE527536T1 (de) 2011-10-15
WO2006100064A1 (de) 2006-09-28
CN101147057B (zh) 2011-12-21
JP4825263B2 (ja) 2011-11-30
CA2598586A1 (en) 2006-09-28
JP2008534920A (ja) 2008-08-28
ES2374541T3 (es) 2012-02-17
HK1118606A1 (en) 2009-02-13
CN101147057A (zh) 2008-03-19
US20080060424A1 (en) 2008-03-13
CA2598586C (en) 2013-09-03
US20100278693A1 (en) 2010-11-04
US7763470B2 (en) 2010-07-27
EP1705480A1 (de) 2006-09-27

Similar Documents

Publication Publication Date Title
EP1705480B1 (de) Testelement zur Analyse von Körperflüssigkeiten
EP1789192B1 (de) Analytisches testelement
EP0949002B1 (de) Verfahren zur Herstellung von analytischen Hilfsmitteln
DE60306711T2 (de) Verfahren und Vorrichtung zur Sammlung von physiologischen Proben
US7322942B2 (en) Integrated disposable for automatic or manual blood dosing
DE19826957C2 (de) Vorrichtung zum Bestimmen eines Analyten in einem Körperfluid
EP2654955B1 (de) Verfahren zum mischen wenigstens einer probenlösung mit reagenzien
DE60311176T2 (de) Verfahren zur Herstellung von Vorrichtungen zur Entnahme von physiologischen Proben
DE60302705T2 (de) Vorratsbehältnis für Teststreifen
EP1714614B1 (de) Analytisches Hilfsmittel
EP1287785B1 (de) Analytisches Hilfsmittel mit Lanzette und Testelement
EP1868491B1 (de) Analytisches hilfsmittel mit lanzette und testelement
DE69737332T2 (de) Vorrichtung und Verfahren zur Analyse einer Probe
EP1522343B1 (de) Analytisches Testelement umfassend ein hydrophiles Netzwerk zur Bildung eines Kapillarkanals, dessen Verwendung und Verfahren zur Bestimmung eines Analyten in einer Flüssigkeit
EP1507589B1 (de) Vorrichtung zur probennahme von flüssigen proben
WO2011018172A1 (de) Testelement zur analyse einer körperflüssigkeit
EP3361253B1 (de) Vorrichtung zur gezielten prüfung und anzeige der ab- bzw. anwesenheit von analyten in einer flüssigen probe
EP2059169B1 (de) Medizinisches hilfsmittel
DE102015203719A1 (de) Vorrichtung und Verfahren zur Atemgasanalyse und Atemgasanalysegerät

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

AKX Designation fees paid
17P Request for examination filed

Effective date: 20070530

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20070820

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: F. HOFFMANN-LA ROCHE AG

Owner name: ROCHE DIAGNOSTICS GMBH

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 502005011958

Country of ref document: DE

Owner name: ROCHE DIABETES CARE GMBH, DE

Free format text: FORMER OWNERS: ROCHE DIAGNOSTICS GMBH, 68305 MANNHEIM, DE; F. HOFFMANN-LA ROCHE AG, 4070 BASEL, CH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502005011958

Country of ref document: DE

Effective date: 20111201

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2374541

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20120217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111005

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20111005

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111005

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120205

REG Reference to a national code

Ref country code: IE

Ref legal event code: FD4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120106

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111005

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111005

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111005

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111005

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120105

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111005

Ref country code: IE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111005

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111005

26N No opposition filed

Effective date: 20120706

BERE Be: lapsed

Owner name: ROCHE DIAGNOSTICS G.M.B.H.

Effective date: 20120331

Owner name: F. HOFFMANN-LA ROCHE A.G.

Effective date: 20120331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120331

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502005011958

Country of ref document: DE

Effective date: 20120706

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120331

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120331

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120331

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 527536

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120322

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120322

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120322

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050322

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 502005011958

Country of ref document: DE

Owner name: ROCHE DIABETES CARE GMBH, DE

Free format text: FORMER OWNER: ROCHE DIAGNOSTICS GMBH, 68305 MANNHEIM, DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20161220

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20170309

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20170308

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20180401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180322

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20190911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180323

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240220

Year of fee payment: 20

Ref country code: GB

Payment date: 20240221

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240220

Year of fee payment: 20

Ref country code: FR

Payment date: 20240220

Year of fee payment: 20